Left ventricular hypertrophy: A "factor of risk": Mass is reversible, but is the risk?

Journal of the American College of Cardiology

Volumn 43, Issue 12, 2004, Pages 2216-2218

  Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAMIPRIL;

CARDIOVASCULAR RISK; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAPHY MONITORING; EXTRACELLULAR MATRIX; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HUMAN; ISCHEMIC HEART DISEASE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION; Q WAVE; RADIOCARDIOGRAPHY; RISK FACTOR; X RAY PICTURE;

EID: 2942511896     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.024     Document Type: Editorial

References (30)

1. Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004;43:2207-15.
2. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 2004;43:2200-6.
3. Kannel W.B., Dawber T.R., Kagan A., et al. Factors of risk in the development of coronary heart disease. Six years' follow-up experience. Ann Intern Med. 55:1961;33-56
4. McKee P.A., Castelli W.P., McNamara O.M., et al. The natural history of congestive heart failure. The Framingham Heart Study. N Engl J Med. 285:1971;1441-1446
5. Vasan R.S., Benjamin E.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure An epidemiologic perspective. J Am Coll Cardiol. 26:1995;1565-1574
6. Frohlich E.D., Tarazi R.C., Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation. 44:1971;446-455
7. Dunn F.G., Chandraratna P., de Carvalho J.G.R., et al. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol. 39:1977;789-795
8. Levy D., Anderson K.M., Savage D.D., et al. Echocardiographically detected left ventricular hypertrophy Prevalence and risk factors: the framingham heart study. Ann Intern Med. 108:1988;7-13
9. Frohlich E.D., Tarazi R.C. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol. 44:1979;959-963
10. Pegram B.L., Ishise S., Frohlich E.D. Effect of methyldopa, clonidine, and hydralazine on cardiac mass and hemodynamics in Wistar-Kyoto and spontaneously hypertensive rats. Cardiovasc Res. 16:1982;40-46
11. Frohlich E.D. Hemodynamics and other determinants in development of left ventricular hypertrophy. Conflicting factors in its regression. Fed Proc. 42:1983;2709-2715
12. Frohlich E.D. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol. 84:1989;19S-23S
13. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008
14. Pfeffer J.M., Pfeffer M.A., Fletcher P.J., et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol. 242:1982;H766-H784
15. Dunn F.G., Oigman W., Ventura H.O., et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 53:1984;105-108
16. Shapiro L.M., McKenna W.J. Left ventricular hypertrophy. Relation of structure to diastolic function in hypertension. Br Heart J. 51:1984;637-642
17. Frohlich E.D. Risk mechanisms in hypertensive heart disease. Hypertension. 34:1999;782-789
18. Opherk D., Nall G., Zebe H., et al. Reduction of coronary reserve A mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 69:1984;1-7
19. Weber K.T., Sun Y., Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 23:1994;869-877
20. Gonzalez A., Lopez B., Ravassa S., et al. Stimulation of cardiac apoptosis in essential hypertension Potential role of angiotensin ii. Hypertension. 39:2002;75-80
21. Schwartzkopff B., Brehm M., Mundhenke M., et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 36:2000;220-225
22. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive hear disease. Circulation. 102:2000;1388-1393
23. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 105:2002;2512-2517
24. Fortuno M.A., Gonzalez A., Ravassa S., Lopez B., Diez J. Clinical implications of apoptosis in hypertensive heart disease. Am J Physiol Heart Circ Physiol. 284:2003;H1495-H1506
25. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy Comparison to necropsy findings. Am J Cardiol. 57:1986;450-458
26. Frohlich E.D. Is reversal of left ventricular hypertrophy in hypertension beneficial? Hypertension. 18:1991;133-138
27. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients A meta analysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110
28. Re R.N. The nature of intracrine peptide hormone action. Hypertension. 34:1999;534-538
29. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 213:1970;1143-1152
30. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.